Introduction
============

Liver dysfunction is a global health issue and currently the only successful treatment for end-stage liver disease is liver transplantation ([@b1-mmr-21-03-1051]). However, due to donor shortage and immunological rejection, its clinical application is limited ([@b2-mmr-21-03-1051]). To this end, bio-artificial liver support systems and hepatocyte transplantation are two potential complementary therapies for patients with end-stage liver disease. Developments in stem cells, particularly mesenchymal stem cells (MSCs), have highlighted a new source of liver cells as they have the ability to differentiate into hepatocyte-like cells via the addition of cytokines *in vitro* ([@b3-mmr-21-03-1051]).

MSCs can be isolated from various body tissues, including amniotic fluid, umbilical cord placenta, bone marrow and adipose tissue ([@b4-mmr-21-03-1051],[@b5-mmr-21-03-1051]). Human umbilical cord (Hu)MSCs are recognized as an ideal supply for cell therapy because of their low immunogenicity, abundant source and freedom from ethical issues ([@b6-mmr-21-03-1051]). Our recent study showed the efficacy of HuMSCs in regenerative medicine and that HuMSCs hold numerous advantages over bone marrow-derived MSCs (BMSCs), including higher potential for proliferation and differentiation abilities *in vitro* ([@b7-mmr-21-03-1051]). However, the efficacy of hepatic differentiation of MSCs is still insufficient for clinical application ([@b8-mmr-21-03-1051]). Therefore, it is necessary to find a new differentiation method to achieve a higher efficient transdifferentiation.

Long noncoding RNAs (lncRNAs) are a class of RNAs \>200 nucleotides in length that cannot encode proteins. It has recently been reported that some lncRNAs can play important roles in cellular activities, including cell proliferation, self-renewal, differentiation and apoptosis ([@b9-mmr-21-03-1051],[@b10-mmr-21-03-1051]). For example, HOTAIR improves MSC differentiation and is associated with senescence-associated DNA methylation ([@b11-mmr-21-03-1051]).

Studies on lncRNA cancer upregulated drug resistant (CUDR) have mainly focused on cancer cells and other related molecular mechanisms. It is a novel noncoding RNA gene, which was found to influence the proliferation, apoptosis and cell cycle progression of colorectal cancer cells ([@b12-mmr-21-03-1051]). Moreover, CUDR has the ability to promote liver cancer growth and hepatocyte-like stem cell malignant transformation epigenetically by cooperating with set domain-containing 1A, histone lysine methyltransferase ([@b13-mmr-21-03-1051]). Little is known regarding the expression of CUDR in hepatocytes or in the differentiation of hepatocytes. A previous study has highlighted the role of CUDR in embryo stem cell growth and hepatic differentiation ([@b14-mmr-21-03-1051]). However, the function of CUDR in the hepatic differentiation of MSCs remains unclear. The present study demonstrated that expression of CUDR significantly increased during the hepatic differentiation of HuMSCs, and that it promoted hepatic differentiation. Moreover, these results showed that CUDR not only regulated liver-enriched factors, but also inhibited the Wnt/β-catenin pathway.

Materials and methods
=====================

### Culture and differentiation of HuMSCs

HuMSCs were purchased from Beijing Beina Chuanglian Biotechnology Institute. Cells were cultured in 25-cm^2^ culture flasks containing HyClone™ Dulbecco\'s modified Eagle\'s medium (HyClone; GE Healthcare Life Sciences), supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.). Cells were grown at 37°C under 5% CO~2~ atmosphere. The culture medium was replaced every 3 days and the HuMSCs were digested with trypsin (Gibco; Thermo Fisher Scientific, Inc.) once they reached 70--80% confluency. The cells in the fourth passage were used for further differentiation. Before hepatic differentiation, the multipotency of the cultured HuMSCs was confirmed by differentiation experiments. The cells were treated with osteogenic medium containing L-glutamine, decamethasone, ascorbate and β-glycerophosphate (Sigma-Aldrich; Merck KGaA) and chondrogenic medium containing h-Insulin, L-glutamin, dexamethasone, indomethacin and 3-isobuty-I-methyl-xanthine (Sigma-Aldrich; Merck KGaA) according to previous studies ([@b15-mmr-21-03-1051],[@b16-mmr-21-03-1051]).

### Alizarin red staining

Cells were washed by PBS twice and fixed in 10% paraformaldehyde for at 4°C for 10 min. Alizarin red (0.1%) was added at 37°C for 30 min. Following washing in distilled water, they were observed under an inverted microscope (magnification, ×100).

### Type II collagen staining

Cells were fixed with 4% paraformaldehyde at 4°C for 30 min, permeabilized with 2% Triton X-100 and labeled with monoclonal antibody anti-type II collagen antibody (SC-52658, Santa Cruz Biotechnology, Inc.). They were observed under an inverted microscope (magnification, ×100).

### Hepatic differentiation

To induce hepatic differentiation, the growth medium was replaced with differentiation medium described below when cells in passage four reached 80% confluency, as based on a previous protocol ([@b3-mmr-21-03-1051]). Differentiation was induced by treating MSCs with liver-specific growth factors: Days 0--2, Iscove\'s modified Dulbecco\'s medium (IMDM, Gibco; Thermo Fisher Scientific, Inc.) with 20 ng/ml epidermal growth factor (PeproTech, Inc.) and 10 ng/ml basic fibroblast growth factor (bFGF; PeproTech, Inc.); days 3--9, IMDM supplemented with 20 ng/ml hepatocyte growth factor (PeproTech, Inc.), 10 ng/ml bFGF and 0.61 g/ml nicotinamide (Sigma-Aldrich; Merck KGaA); from day 9 onwards, IMDM containing 20 ng/ml oncostatin M (PeproTech, Inc.), 1 µmol/l dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml insulin/transferring/selenium (Sigma-Aldrich; Merck KGaA). The hepatic differentiation medium was replaced every 3 days. The progression of differentiation from HuMSCs to hepatocytes (at days 14 and 28) was analyzed.

### Immunocytochemistry analysis

After induction, cells were fixed with 4% paraformaldehyde for 30 min (Beyotime Institute of Biotechnology) and blocked in 10% BSA (Gibco; Thermo Fisher Scientific, Inc.) at 37°C for 30 min. Slides were then incubated with primary antibodies (ALB sc-271605, AFP sc-8399, CYP3A4 sc-365415 and β-catenin sc-47724, Santa Cruz Biotechnology, Inc.), including mouse monoclonal anti-albumin (ALB; 1:200), mouse monoclonal anti-α fetoprotein (AFP; 1:200), mouse monoclonal anti-cytochrome P450 3A4 (CYP3A4; 1:200) and mouse monoclonal anti-β-catenin (1:200) overnight at 4°C. After washing, cells were incubated with FITC-conjugated (Dylight 594 and Alexa 488) goat anti-mouse immunoglobulin G secondary antibody (1:1,000, sc-516140; Santa Cruz Biotechnology, Inc.) at 37°C for 45 min. After rinsing, the nuclei were stained with DAPI (Sigma-Aldrich; Merck KGaA) at 37°C for 5 min and cells were then observed with a fluorescence microscope (Olympus Corporation) at ×200 magnification.

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA from cells was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The cDNA was synthesized using PrimeScript™ RT reagent kit (Takara Biotechnology Co., Ltd.) in a 20 µl reaction containing 100--200 ng of total RNA. All samples were reacted at 37°C for 60 min, heated at 95°C for 5 min, and finally held at 4°C. The products were then quantified via RT-qPCR using SYBR Green Master Mix (Takara Biotechnology Co., Ltd.) with the primer sequences listed in [Table I](#tI-mmr-21-03-1051){ref-type="table"}. The analysis of the melting curve was achieved to exclude nonspecific amplification products ([@b16-mmr-21-03-1051]). Human GAPDH was used as an internal control for PCR. Thermocycling conditions were: Initial denaturation: 95°C for 30 sec, 95°C for 5 sec and 60°C for 34 sec for 30 cycles. Fold changes were calculated using the relative quantification (2^−ΔΔCq^) method ([@b17-mmr-21-03-1051]).

### CUDR transfection

CUDR lentiviral plasmid LV5-CUDR-homo and negative control vectors LV3-NC were purchased from Shanghai GenePharma Co., Ltd. Cells were seeded in 6-well plates (5×10^4^ cells/well) and then incubated with 1×10^8^ TU/ml lentivirus (4 µl), 5 µg/ml polybrene (Shanghai GenePharma Co., Ltd.) and complete medium. After transfection, lentivirus-infected HuMSCs were subjected to puromycin for selection. After 7 days of selection, the stable transfected cell line was identified, and overexpression of CUDR was confirmed by RT-qPCR analysis.

### ELISA

The cell culture supernatants were collected after hepatic differentiation of HuMSCs on 6-well plates. The human ALB and blood urea nitrogen (BuN) concentrations of culture supernatants were measured using ELISA kits (ALB, ab108788, Abcam; BuN, SKT-213-192, StressMarq Biosciences Inc.), referring to the manufacturer\'s protocol.

### Western blotting

Cells were lysed in RIPA buffer (Invitrogen; Thermo Fisher Scientific, Inc.) and a protease inhibitor cocktail before being heated at 95°C for 10 min. Then, the lysates were centrifuged at 15,000 × g for 25 min at 4°C to remove the debris. 10 µg protein per lane was separated by 10% SDS-PAGE and transferred to 0.45-µm PVDF membranes. Primary antibodies against hepatocyte nuclear factor 4α (HNF4α, sc-374299, Santa Cruz Biotechnology, Inc.), hepatocyte nuclear factor 3β (HNF3β, sc-374376, Santa Cruz Biotechnology, Inc.), hepatocyte nuclear factor 6 (HNF6, sc-365318, Santa Cruz Biotechnology, Inc.), enhanced binding protein α (CEBPα, sc-133239, Santa Cruz Biotechnology, Inc.), β-catenin (sc-47724, Santa Cruz Biotechnology, Inc.) and GAPDH (all at 1:2,000 dilution) were incubated overnight at 4°C and washed with TBS containing 0.1% Tween-20. Secondary antibody (1:5,000; Santa Cruz Biotechnology, Inc. goat anti-mouse IgG-HRP, sc-2005) was incubated with membranes for 2 h at room temperature. Visualization was performed with an enhanced chemiluminescence substrate (Thermo Fisher Scientific, Inc.) and the band intensities were analyzed using Image J software (version 1.8.0, National Institutes of Health) for quantitative calculation.

### Dual-luciferase reporter gene assay

Cells were first seeded into 24-well plates and co-transfected with TOP/FOP Flash plasmid and Renilla TK-Luciferase vector (Shanghai GenePharma Co., Ltd.) with Lipofectamine^®^ 2000 reagent (11668027, Invitrogen). Then, 48 h after transfection, cells were harvested and lysed for luciferase assay (Promega Corporation). The luciferase activity of each samples was normalized with its respective Renilla luciferase activity.

### Statistical analysis

The significant differences between mean values obtained from at least three independent experiments were received. Each value was presented as the mean ± SD. ANOVA followed by a post-hoc Tukey\'s test was used for comparisons between various groups, with P\<0.05 considered statistically significant. Statistical analysis was carried out using SPSS 16.0 software (SPSS, Inc.).

Results
=======

### Hepatocyte differentiation of HuMSCs in vitro

HuMSCs were successfully induced to osteoblasts and chondrocytes, as evidenced by positive staining for alizarin red and type II collagen, respectively ([Fig. 1A](#f1-mmr-21-03-1051){ref-type="fig"}). After treatment with hepatocyte induction media, the morphology of HuMSCs observed by phase contrast microscopy did not notably change until day 14. However, from day 15, the cells were found to modify their phenotype from a spindle to a polygonal shape, and granules in the cytoplasm also gradually accumulated ([Fig. 1B](#f1-mmr-21-03-1051){ref-type="fig"}). The progression of differentiation from HuMSCs to hepatocytes (at days 14 and 28) was analyzed via RT-qPCR at the same time, and the levels of hepatocyte-specific mRNAs such as ALB, AFP, CYP3A4 and HNF4α were examined. It was shown that ALB, AFP, CYP3A4 and HNF4α mRNA expression increased significantly during the period ([Fig. 1C](#f1-mmr-21-03-1051){ref-type="fig"}). The level of GAPDH was used to normalize the results, and results obtained from HuMSCs cultured in growth medium and primary hepatocytes were compared. Cells of day 0 were cultured in growth medium and cells of day 14,28 were cultured in differentiation medium. Hepatocytes were acquired from Beijing Beina Chuanglian Biotechnology Institute and were cultured in L-DMEM. Additionally, the protein levels of ALB, AFP and CYP3A4 were analyzed via immunofluorescence staining after 28 days of induction. These three proteins stained positive in HuMSC-derived hepatocyte-like cells. Additionally, undifferentiated cells, as the control group, were negative for AFP and CYP3A4, while the ALB staining was lower than hepatocyte-like cells ([Fig. 1D](#f1-mmr-21-03-1051){ref-type="fig"}). The level of CUDR was also examined during differentiation, and was gradually upregulated over time ([Fig. 1E](#f1-mmr-21-03-1051){ref-type="fig"}).

### Overexpression of CUDR in hepatic differentiation

The overexpression of CUDR in hepatic differentiation was further probed by using a lentiviral construct. After confirming successful transfection by fluorescence imaging (data not shown), HuMSCs were selected by puromycin for at least 7 days. The results of RT-qPCR demonstrated that CUDR remained highly expressed during differentiation relative to the negative control ([Fig. 2A](#f2-mmr-21-03-1051){ref-type="fig"}). To explore the role of CUDR overexpression in hepatic differentiation, mRNAs of several hepatic markers were compared between HuMSCs transfected with CUDR, and HuMSCs transfected with the negative control, after 14 and 28 days of induction. As presented in [Fig. 2C](#f2-mmr-21-03-1051){ref-type="fig"}, the expression levels of ALB, CYP3A4, tyrosine aminotransferase (TAT), glucose-6-phosphatase (G6P) and α1-antitrypsin (α1AT) mRNA in the CUDR overexpression group were higher than those in the control group (P\<0.05) at day 14 and day 28. The expression of AFP in the CUDR overexpression group was lower than that in the control group at day 28, indicating that these cells had a more mature status. Furthermore, the ALB and BuN production at day 14 and day 28 showed a significant increase in CUDR ([Fig. 2B](#f2-mmr-21-03-1051){ref-type="fig"}). The expression of ALB, CYP3A4 and AFP proteins were also examined by immunostaining after 28 days of induction. Statistical analysis demonstrated that the HuMSCs transfected with CUDR showed higher expression of ALB and CYP3A4 compared with the control group, while the expression of AFP protein level was lower compared with the control group, which was consistent with the results of RT-qPCR ([Fig. 2D](#f2-mmr-21-03-1051){ref-type="fig"}).

### CUDR upregulates liver-enriched transcriptional factors

It has been demonstrated by several studies that the coordinated expression of liver-enriched transcriptional factors is required for the hepatic differentiation and biological functions of hepatocyte cells ([@b18-mmr-21-03-1051]--[@b20-mmr-21-03-1051]). It was shown in the control group that the expression levels of HNF4α, HNF3β, HNF6 and CEBPα were low at days 14 and 28. After the overexpression of CUDR, these genes were expressed at a higher level on days 14 and 28 ([Fig. 3A](#f3-mmr-21-03-1051){ref-type="fig"}), which indicated their possible relationship with CUDR. Protein levels of liver-enriched factors were examined via western blotting and the results were in accordance with RT-qPCR analysis ([Fig. 3B](#f3-mmr-21-03-1051){ref-type="fig"}).

### CUDR downregulates β-catenin

As is commonly known, nuclear translocation plays an important role in Wnt/β-catenin signaling activation ([@b21-mmr-21-03-1051]). To explore the mechanism underlying the relationship between CUDR and increased hepatic differentiation, the expression of β-catenin and the sub-cellular localization in HuMSCs were examined in the presence or absence of overexpression of CUDR. As shown in [Fig. 4A](#f4-mmr-21-03-1051){ref-type="fig"}, β-catenin was strongly expressed and mostly localized in the nucleus in the control group. However, following CUDR overexpression, the nuclear staining of β-catenin was markedly reduced. The TOP/FOP reporter assay revealed that the Wnt/β-catenin signaling was significantly downregulated by CUDR overexpression ([Fig. 4B](#f4-mmr-21-03-1051){ref-type="fig"}). In line with these data, overexpression of CUDR significantly suppressed the expression of β-catenin mRNA and protein ([Fig. 4C and D](#f4-mmr-21-03-1051){ref-type="fig"}).

Discussion
==========

It has been demonstrated that HuMSCs can differentiate into hepatocyte-like cells under certain conditions *in vitro*. HuMSCs have a major advantage over BMSCs and other sources of stem cells as they can be obtained non-invasively from umbilical cords. The fact that they are in vast abundance, free from ethical problems, cause a less pronounced immune response and offer the possibility to be cultured over a long time period *in vitro* make HuMSCs the ideal choice for the present study ([@b6-mmr-21-03-1051]).

To generate hepatocyte-like cells, numerous researchers have engaged in finding simpler and more efficient procedures from various types of stem cells. In this study, HuMSCs were induced under hepatic differentiation media that included different cytokines and growth factors, which have been demonstrated to be important during the differentiation into hepatocyte-like cells. Then, hepatocyte-specific markers were examined to confirm the hepatic features of hepatocyte-like cells. Besides the changes of morphology that were examined by phase contrast microscopy, expression of hepatocyte-related genes such as AFP, ALB, CYP3A4 and HNF4α were also confirmed via RT-qPCR analysis. Moreover, it was shown by immunofluorescence that ALB, AFP and CYP3A4 were expressed at a translation level.

The importance of specific lncRNAs participating in physiological and pathological processes, including the differentiation of various cells has been shown. For instance, Huang *et al* ([@b22-mmr-21-03-1051],[@b23-mmr-21-03-1051]) demonstrated that H19 could improve the osteogenic capacity of MSCs through the transforming growth factor-β1/Smad family member 3/histone deacetylase signaling pathway, while it inhibited adipocyte differentiation of BMSCs through epigenetic modulation of histone deacetylases. The lncRNA RAR related orphan receptor C contributes to SOX9 expression and chondrogenic differentiation of HuMSCs ([@b24-mmr-21-03-1051]). Although CUDR is known to be involved in carcinogenesis at the transcriptional and post-transcriptional levels, CUDR is seldom reported to regulate hepatic differentiation ([@b14-mmr-21-03-1051]). The results of the present study showed that the expression of CUDR gradually increased following the differentiation of HuMSCs. This study attempted to focus on the overexpression of CUDR in the hepatic differentiation of HuMSCs. In order to show this, the lentiviral transduction procedure was used to overexpress CUDR in HuMSCs, and the level of CUDR overexpression was examined using RT-qPCR. This revealed a continuous high expression of CUDR in transfected HuMSCs throughout the process of differentiation.

As expected, CUDR overexpression in HuMSCs resulted in a significant upregulation of several genes related to hepatic function. It was revealed by RT-qPCR that the expression levels of ALB, CYP3A4, TAT, G6P and α1AT were higher than in the control group, whereas AFP was expressed on a lower level, indicating a more mature hepatocyte character ([@b25-mmr-21-03-1051]). Furthermore, the secretion of ALB and the production of urea in the transduced cells were detected using ELISA. The results also demonstrated that CUDR overexpression induced a more functional hepatocyte-like cell. Additionally, the findings of immunofluorescence analysis of the ALB, AFP and CYP3A4 proteins were in accordance with the RT-qPCR results.

As commonly known, the coordinated expression of liver-enriched transcriptional factors is required for the hepatic differentiation and biological functions of hepatocytes ([@b19-mmr-21-03-1051],[@b20-mmr-21-03-1051]). In the present study, the liver-enriched factors mRNA HNF4α, HNF3β, HNF6 and CEBPα began to increase after 14 days of induction as determined via RT-qPCR analysis. Overexpression of CUDR upregulated the liver-enriched factors compared with the control group, which indicated that CUDR may improve the function of hepatocyte-like cells via the regulation of liver-enriched factors.

Accumulating evidence indicates that the downregulation of Wnt/β-catenin signaling contributes to the hepatic differentiation of MSCs ([@b26-mmr-21-03-1051]--[@b28-mmr-21-03-1051]). Several lncRNAs were found to participate in Wnt/β-catenin signaling, including lnc liver regeneration 1, lnc transcription factor 7, and lnc β-Catm ([@b29-mmr-21-03-1051]--[@b31-mmr-21-03-1051]). The Wnt/β-catenin signaling pathway was focused on in the present study as a possible mechanism for hepatic differentiation induced by CUDR overexpression. It was shown that the overexpression of CUDR prevented the translocation of β-catenin to the nucleus, and suppressed the activity of this pathway. Therefore, the enhanced hepatic differentiation of HuMSCs caused by CUDR may be linked to the downregulation of the Wnt/β-catenin signaling pathway. However, the mechanism of how CUDR affects β-catenin level and sub-cellular localization needs further investigation.

To conclude, the findings of the present study indicated that CUDR may be a prominent factor in the hepatic differentiation of HuMSCs. This suggested that the overexpression of CUDR could serve as a valuable procedure to produce efficient and functional hepatocyte-like cells for transplantation. Therefore, this could be very useful in improving hepatic differentiation and providing a regenerative therapy for liver disease. However, further studies are required to clarify the particular mechanisms during hepatic differentiation.
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![Hepatic differentiation of HuMSCs. (A) HuMSCs were identified by osteogenic and chondrogenic differentiation. (B) Morphological changes observed as HuMSCs differentiated into hepatocytes with the addition of cytokines. (C) mRNA levels of ALB, AFP, CYP3A4 and HNF4α after differentiation were analyzed via RT-qPCR. (D) ALB, AFP, CYP3A4 protein levels after differentiation were analyzed by immunocytochemistry. (E) Expression of CUDR was analyzed via RT-qPCR. All experiments were performed three times independently. \*P\<0.05 vs. Day 0 group. All experiments were performed three independent times. HuMSCs, human umbilical cord mesenchymal stem cells; ALB, albumin; AFB, α fetoprotein; CYP3A4, cytochrome P450 3A4; HNF4α, hepatocyte nuclear factor 4α; RT-qPCR, reverse transcription-quantitative PCR; CUDR, cancer upregulated drug resistant.](MMR-21-03-1051-g00){#f1-mmr-21-03-1051}

###### 

Effect of CUDR overexpression on hepatic differentiation. (A) RT-qPCR analysis of CUDR expression levels in HuMSCs transduced with lentiviruses containing either CUDR or negative control. (B) ALB and BuN concentration of the supernatant were analyzed by ELISA. (C) Hepatic differentiation was evaluated with reverse transcription-quantitative PCR analysis of ALB, AFP, CYP3A4, G6P, TAT and α1AT. (D) Comparison of ALB, CYP3A4 and AFP protein between HuMSCs transfected with CUDR and cells cultured in medium containing cytokines via immunocytochemistry. \*P\<0.05 vs. control group. All experiments were performed three independent times. HuMSCs, human umbilical cord mesenchymal stem cells; ALB, albumin; AFB, α fetoprotein; CYP3A4, cytochrome P450 3A4; CUDR, cancer up-regulated drug resistant; BuN, blood urea nitrogen; G6P, glucose-6-phosphatase; TAT, tyrosine aminotransferase; α1AT, α1-antitrypsin.
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![CUDR promotes hepatic differentiation by regulating liver-enriched factors. (A) mRNA of HNF4α, HNF3β, HNF6 and CEBPα were analyzed by reverse transcription-quantitative PCR after 14 and 28 days of differentiation. (B) Protein levels of HNF4α, HNF3β, HNF6 and CEBPα were analyzed by western blot analysis after 14 and 28 days of differentiation. \*P\<0.05 vs. control group. All experiments were performed three independent times. HNF4α, hepatocyte nuclear factor 4α; CUDR, cancer upregulated drug resistant; HNF3β, hepatocyte nuclear factor 3β; HNF6, hepatocyte nuclear factor 6; CEBPα, enhanced binding protein α.](MMR-21-03-1051-g03){#f3-mmr-21-03-1051}

![CUDR inhibits Wnt signaling activity by decreasing β-catenin cyto-nuclear translocation. (A) Immunocytochemistry staining for the localization of β-catenin in hepatocyte-like cells after differentiation when transfected with control or CUDR. (B) TOP/FOP assay showing the decreased activity of Wnt signaling in the hepatocyte-like cells with overexpression of CUDR. (C) RT-qPCR analysis showing CUDR transduction downregulated the mRNA expression of β-catenin. (D) Result of western blot analysis was in accordance with RT-qPCR. \*P\<0.05 vs. control group. All experiments were performed three independent times. CUDR, cancer upregulated drug resistant; RT-qPCR, reverse transcription-quantitative PCR.](MMR-21-03-1051-g04){#f4-mmr-21-03-1051}

###### 

Sequences of reverse transcription-quantitative PCR primers.

  Genes       Primer sequence (5′-3′)        Fragment length (bp)   Annealing temperature
  ----------- ------------------------------ ---------------------- -----------------------
  ALB         F: TGCTTGAATGTGCTGATGACAGGG                           
              R: AAGGCAAGTCAGCAGGCATCTCATC   162                    60
  AFB         F: GAAACCCACTGGAGATGAACAGTC                           
              R: AAGTGGGATCGATGCAGGA         190                    60
  TAT         F: TGAGCAGTCTGTCCACTGCCT                              
              R: ATGTGAATGAGGAGGATCTGAG      359                    60
  G6P         F: GCTGGAGTCCTGTCAGGCATTGC                            
              R: TAGAGCTGAGGCGGAATGGGAG      349                    60
  CYP3A4      F: TGTGCCTGAGAACACCAGAG                               
              R: GCAGAGGAGCCAAATCTACC        202                    60
  α1AT        F: CTGGGACAGTGAATCGACAATGC                            
              R: TCTGTTTCTTGGCCTCTTGGTG      560                    54
  GAPDH       F: AGAAGGCTGGGGCTCATTTG                               
              R: AGGGCCATCCACAGTCTTC         258                    52
  HNF4α       F: GCACCAACCTCAACGC                                   
              R: AGGCTGCTGTCCTCATAG          313                    56
  CUDR        F: ACGCTAACTGGCACCTTGTT                               
              R: CTCCGGACTGCTTCAAGTGT        124                    56
  HNF3β       F: GCACCTGCAGATTCTGATTTT                              
              R: GACTTCCCTGCAACAACAGC          66                   60
  HNF6        F: CCTGGAGCAAACTCAAATCC                               
              R: TTCTTTCCTTTTGCATGCTG        116                    60
  CEBPα       F: CAACACTTGTATCTGGCCTCTG                             
              R: CGAGCAAAACCAAAACAAAAC       112                    60
  β-catenin   F: ATTGTCCACGCTGGATTTTC                               
              R: AGGTCTGAGGAGCAGCTTCA        142                    58

ALB, albumin; AFB, α fetoprotein; CYP3A4, cytochrome P450 3A4; HNF4α, hepatocyte nuclear factor 4α; RT-qPCR, reverse transcription quantitative PCR; CUDR, cancer up-regulated drug resistant; CUDR, cancer upregulated drug resistant; HNF3β, hepatocyte nuclear factor 3β; HNF6, hepatocyte nuclear factor 6; CEBPα, enhanced binding protein α; G6P, glucose-6-phosphatase; TAT, tyrosine aminotransferase; α1AT, α1-antitrypsin.
